Cromos Pharma, where the patients are

Massachusetts General Hospital

Infinity appoints Baselga, Berkowitz to board of directors

Thursday, March 13, 2014 11:26 AM

Infinity Pharmaceuticals has appointed José Baselga M.D., Ph.D., and Jeff Berkowitz as independent members of its board of directors. Baselga, physician-in-chief at Memorial Sloan-Kettering Cancer Center, is an accomplished clinician and a thought leader in the PI3K field. Berkowitz, as the president of Walgreens Boots Alliance Development in Europe, has experience in pharmaceuticals, pharmacy, distribution and market access, pricing and reimbursement.

More... »

CRF Health eCOA webinar series

MGH, Broad Institute, Amgen collaborate on IBD therapies

Friday, January 17, 2014 11:44 AM

Massachusetts General Hospital (MGH), the Broad Institute and Amgen have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists with experience in clinical medicine, IBD biology, human genetics, genomic technology and drug discovery to work together to help create a new world of therapeutic options for IBD patients.

More... »

Perrigo names board of directors

Friday, December 20, 2013 02:11 PM

Dublin, Ireland-based Perrigo has announced the appointment of its board of directors, effective until Perrigo’s annual general meeting scheduled for November 2014. The appointment of the Perrigo board follows the completion of Perrigo’s acquisition of Elan in a cash and stock transaction valued at approximately $8.6 billion. The transaction will create a global healthcare company with a growth profile.

More... »

Michael Seiden named CMO for McKesson Specialty Health, U.S. Oncology Network

Friday, September 6, 2013 03:09 PM

McKesson Specialty Health and The U.S. Oncology Networkhave appointed of Michael V. Seiden, M.D., Ph.D. as chief medical officer.

More... »

Sanofi, Mass. General Hospital launch oncology research collaboration

Thursday, October 11, 2012 07:00 AM

Global healthcare company Sanofi has formed a two-year agreement with Massachusetts General Hospital (MGH) aimed at furthering translational medicine research to develop new treatments for various types of hematological malignancies and solid tumors.

More... »

Annovation Biopharma raises $8M to develop novel anesthetics

Tuesday, September 11, 2012 08:00 AM

Annovation Biopharma, a biotech focused on safer therapies for anesthesia, has raised $8 million in a Series A financing led by Atlas Venture, Partners Innovation Fund (PIF) and new strategic investor The Medicines Company. 

More... »

Biomedical Systems to collaborate with Mass. General Hospital

Friday, August 17, 2012 03:19 PM

The imaging division of Biomedical Systems, a global provider of centralized diagnostic services, has formed a collaboration with Massachusetts General Hospital (MGH) to evaluate the efficacy of new drugs and devices.

More... »

EntreMed names two to board of directors

Tuesday, February 7, 2012 01:07 PM

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Wei-Wu He, Ph.D, executive chairman of its board of directors, and Tak W. Mak, Ph.D, as member of the board of directors.

More... »

MGH, Vall d'Hebron Hospital partner with BBVA Foundation in biomarker research

Wednesday, November 23, 2011 10:47 AM

The BBVA Foundation has reported an agreement to underwrite a joint effort between Massachusetts General Hospital and Barcelona's Vall d'Hebron Hospital to search for personalized cancer therapies through biomarker research.

More... »

Researchers use RNA technology to block inflammation

Tuesday, October 11, 2011 01:26 PM

Massachusetts General Hospital (MGH) researchers - along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals - have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication in Nature Biotechnology, the investigators describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage.

More... »

CenterWatch Data Library



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs